Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being hi

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxol

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-B

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov

– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Ac

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie

NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conf

NEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

The consensus price target hints at a 70.5% upside potential for Karyopharm Therapeutics (KPTI). Whi

Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript

Karyopharm Therapeutics NASDAQ: KPTI said it entered 2026 with several near-term clinical and regula

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $1.24 per share versus the Zacks Co

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the

– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mi

NEWTON, Mass., May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET -- NEWTON, Mass.

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with

https://www.sec.gov/Archives/edgar/data/1503802/000119312526204130/d69189ds3.htm

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov

NEWTON, Mass., April 21, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commerc

Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report)'s stock price passed above its fifty d

Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have received a consensus re

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with

Karyopharm Therapeutics shares fall after mixed Phase 3 SENTRY data show spleen reduction gains but

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ:K

HC Wainwright & Co. analyst Robert Burns reiterates Karyopharm Therapeutics (NASDAQ:KPTI) wit

Karyopharm Therapeutics (NASDAQ:KPTI) sees FY2026 sales of $130.000 million-$150.000 million vs $146

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(5.71) per share which missed th

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDA

Karyopharm Therapeutics (NASDAQ:KPTI) narrows FY2025 sales outlook from $140.000 million-$155.000 mi